Cadence Growth Capital (CGC)

Cadence Growth Capital (CGC) is a German growth-stage investor backing established European technology companies, with a posture that favors capital-efficient, profitable or near-profitable businesses scaling beyond Series B. Healthcare exposure is plausible but selective, with the fund’s pattern matching toward B2B software, vertical SaaS, and tech-enabled services rather than therapeutics or regulated devices. For healthcare AI founders, CGC is the right partner if you are at Series B or later, with multi-million Euro ARR, strong unit economics, and a clear path to scaling across European markets — typical fits include digital health platforms with employer or payer revenue, vertical SaaS for healthcare providers, and AI-augmented clinical workflow tools. Check sizes are plausibly EUR 5M to 20M, with an emphasis on growth-stage primary capital and selective secondary. Founders who should approach: European healthcare AI companies with proven commercial traction, a clear roadmap to a EUR 50M-plus revenue business, and a team that is ready for institutional growth-stage governance. Founders who should not approach: seed and Series A teams, pre-revenue science plays, US-only companies, and any business that requires deep clinical or regulatory specialization beyond software-buyer dynamics. Entry path is warm introduction through European venture banks, M&A advisors active in DACH digital health, or earlier-stage VCs preparing companies for growth rounds. Their LinkedIn page lists partners; direct outreach is reasonable when paired with metrics that meet growth-stage thresholds. Be prepared for diligence that emphasizes financial profile, market sizing, and exit pathway — CGC operates with a growth-equity discipline rather than a venture-style power-law lens.